Manufacturing

Feliza Mirasol is the science editor for 

Articles

This $4.1 billion investment to build a second fill/finish manufacturing facility in Clayton, N.C., boosts Novo Nordisk's current 2024 investments in production to $6.8 billion.

Novo Nordisk Aims to Invest $4.1 Billion to Expand Manufacturing Capacity in US

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Podcasts

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish 

Lilly’s investment increase is intended to boost manufacturing capacity at its Lebanon, Ind., site for APIs used in the production of tirzepatide and other pipeline drug candidates.

Lilly Raises Investment in Indiana Site to $9 Billion to Expand API Manufacturing

Videos

Mary Van Gaasbeck, technical services specialist, LS Equipment and Services, at STERIS Life Sciences, notes that automation is key when it comes to effective sterile powder transfer of parenteral drug products.

Taking a Deeper Look at Sterile Powder Transfer in Aseptic Fill/Finish of Parenterals (INTERPHEX 2024)

CDMO White Raven aims to reduce contamination risk and gain the capability to handle multiple product formats with the installation of Cytiva’s SA25 Aseptic Filling Workcell.

White Raven to Increase Manufacturing Efficiency with Cytiva’s Aseptic Filling Workcell

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

Automating the Future of Fill/Finish

The partnership will allow for both companies to provide end-to-end biopharmaceutical manufacturing solutions.

BioCina and NovaCina to Partner on Drug Substance and Product Solutions for Biologics

The company’s Itasca, Ill., facility will offer chemistry, manufacturing, and controls analytical testing support.

Nelson Labs Creates Center of Excellence for Parenteral and Ophthalmic Drug Manufacturing

Biosynth has further strengthened its peptide division with the acquisition of  Pepceuticals.

Biosynth Strengthens Position in Peptide Field through Pepceuticals Acquisition

The newly established business under Advent International and Warburg Pincus will be named Simtra BioPharma Solutions.

Manufacturing, Parenterals and Injectables